Evidence map›Paper›PMID 39966121›Full record

Trial reportJournal of bone and mineral metabolism2025

Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: Interim report (end of 52-week treatment) of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06).

Satoshi Soen, Yukari Uemura, Shiro Tanaka, Yasuhiro Takeuchi, Naoto Endo, Junichi Takada, Satoshi Ikeda, Jun Iwamoto, Nobukazu Okimoto, Sakae Tanaka

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Satoshi SoenSoen Orthopaedics, Osteoporosis and Rheumatology Clinic, 7-12-60 Okamoto, Higashinada-Ku, Kobe, Hyogo, 658-0071, Japan. nra48207@nifty.com.ORCID http://orcid.org/0000-0002-0955-2747
Yukari UemuraBiostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Toyama, Shinjuku-Ku, Tokyo, Japan.
Shiro TanakaDepartment of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Yoshida Konoe-Cho Sakyo-Ku, Kyoto, Japan.
Yasuhiro TakeuchiToranomon Hospital Endocrine Center, Toranomon, Minato-Ku, Tokyo, Japan.
Naoto EndoDepartment of Orthopedic Surgery, Saiseikai Niigata Kenoh Kikan Hospital, Kamisugoro, Sanjo, Niigata, Japan.
Junichi TakadaOsteoporosis Center, Sapporo Maruyama Orthopaedic Hospital, Chuo-Ku, Sapporo, Hokkaido, Japan.
Satoshi IkedaDepartment of Orthopaedic Surgery, Ken-Ai Memorial Hospital, Oaza Kimori, Onga-Machi, Onga, Fukuoka, Japan.
Jun IwamotoBone and Joint Disease Center, Keiyu Orthopaedic Hospital, Akoudacho, Tatebayashi, Gunma, Japan.
Nobukazu OkimotoOkimoto Clinic, Kubi, Yutakamachi, Kure, Hiroshima, Japan.
Sakae TanakaDepartment of Orthopaedic Surgery, Faculty of Medicine, University of Tokyo, Hongo, Bunkyo-Ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1/D)-TPTD and twice-weekly (2/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk. MATERIALS AND

methodsQuestionnaires evaluated overall satisfaction, satisfaction with treatment effectiveness, satisfaction with utility of the self-injection device, and preference for a particular injection regimen after crossover. Quality of life (QOL), visual analogue scale pain scores, and bone mineral density (BMD) were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs).

resultsThe 1/D-TPTD and 2/W-TPTD groups comprised 180 (mean age: 75.9 ± 7.3 years) and 178 (75.4 ± 6.9 years) patients, respectively. After 26 weeks of treatment, the injection regimens were switched and treatment continued for another 26 weeks. Significantly higher persistence was observed in the 1/D-TPTD to 2/W-TPTD group (p = 0.032). No significant between-group differences in overall satisfaction scores or satisfaction with treatment were observed. Satisfaction with the utility of the injection device was significantly higher with the 2/W-TPTD regimen (p < 0.05); this regimen was preferred by 69.4% of patients after crossover (p < 0.001). A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1/D-TPTD to 2/W-TPTD group at 52 weeks (p < 0.05). Significant improvement in the QOL score was observed in both groups (p < 0.05). No serious AEs were reported.

conclusionContinuation of this study will further clarify patient satisfaction, treatment effects, and tolerability.

Indexed as

Bone Density Conservation AgentsOsteoporosisTeriparatideAgedAged, 80 and overBone DensityCross-Over StudiesEast Asian PeopleFemaleHumansJapanMaleMiddle AgedPatient SatisfactionQuality of LifeBone Density Conservation AgentsTeriparatideOsteoporosisPatient satisfactionRandomized controlled trialSelf-injection regimenTeriparatide

Identifiers

PMID39966121
PMCPMC12089251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.